GO:0090104 pancreatic epsilon cell differentiation

Pancreatic epsilon cells are a rare endocrine cell type in the islets of Langerhans that secrete the hormone ghrelin. The Gene Ontology term GO:0090104, pancreatic epsilon cell differentiation, defines the process by which relatively unspecialized cells acquire the specialized structural and functional features of a pancreatic epsilon cell. Understanding this process is important because epsilon cells contribute to endocrine cell diversity in the pancreas, and their differentiation is tightly linked to broader programs of endocrine lineage specification. Single-cell transcriptomic maps of human and mouse pancreas have revealed inter- and intra-cell population structure, including rare endocrine subtypes such as epsilon cells. These maps provide a foundation for identifying the transcriptional and signaling events that drive epsilon-cell differentiation. Epsilon-cell differentiation is also relevant to regenerative medicine and diabetes research. Human pluripotent stem cell-derived islets can now be reconstructed with endocrine subtype completeness, offering a platform to study epsilon-cell development and function in vitro. Transcription factors such as Insm1 regulate pancreatic endocrine cell differentiation and help maintain endocrine cell identity by repressing transdifferentiation between beta and delta cells. Signaling pathways, including TBK1-dependent pathways, regulate pancreatic beta-cell regeneration and may influence endocrine cell plasticity. In addition, microRNA-375 (miR-375) is a conserved regulator of pancreatic endocrine differentiation and has been linked to diabetes. Together, these findings position GO:0090104 within a broader network of transcriptional, signaling, and post-transcriptional control of pancreatic endocrine development. For researchers, GO:0090104 provides a precise ontology term for annotating experiments on ghrelin-expressing endocrine cells, including studies using single-cell RNA sequencing, stem cell differentiation, and genetic perturbation. Because epsilon cells are rare, their differentiation is often studied in the context of whole-islet development and endocrine subtype specification. This article summarizes the definition, mechanisms, key genes, disease relevance, and experimental methods for studying pancreatic epsilon cell differentiation, based on published literature and the QuickGO definition.

GO:0090104, pancreatic epsilon cell differentiation, is the biological process in which relatively unspecialized cells acquire the specialized structural and functional features of a pancreatic epsilon cell. A pancreatic epsilon cell is a cell in the pancreas that secretes ghrelin. The term is synonymous with pancreatic E cell differentiation. This process is part of the broader program of pancreatic endocrine cell development, which generates multiple hormone-producing cell types within the islets of Langerhans.

Pancreatic epsilon cell differentiation is important because it contributes to the cellular diversity of the endocrine pancreas and because epsilon cells are a source of ghrelin, a hormone with metabolic and endocrine functions. Single-cell transcriptomic studies have shown that the human and mouse pancreas contain rare endocrine subtypes, including epsilon cells, and that these populations can be resolved at the transcriptomic level. Understanding how epsilon cells differentiate may inform efforts to generate functional islet cells from pluripotent stem cells, as demonstrated by reconstruction of endocrine subtype-complete human islets. In addition, transcriptional regulators such as Insm1 and signaling pathways such as TBK1-dependent signaling influence endocrine cell differentiation and regeneration, providing mechanistic context for epsilon-cell biology. MicroRNA-375 further highlights post-transcriptional control of pancreatic endocrine differentiation and its link to diabetes.

The following genes and proteins have documented roles in pancreatic endocrine differentiation, islet cell biology, or related processes that inform pancreatic epsilon cell differentiation.

Pancreatic epsilon cell differentiation is regulated by transcriptional, signaling, and post-transcriptional mechanisms. Insm1, a zinc finger transcription factor, regulates pancreatic endocrine cell differentiation and represses beta- to delta-cell transdifferentiation, indicating that it helps maintain endocrine subtype identity. TBK1 signaling regulates regeneration of pancreatic beta-cells, showing that kinase pathways can influence endocrine cell plasticity and regeneration. MicroRNA-375 (miR-375) is a conserved regulator of pancreatic endocrine differentiation and is related to diabetes, providing an example of post-transcriptional control. These regulatory layers operate within the broader context of pancreatic endocrine development, where single-cell transcriptomic maps reveal distinct endocrine populations and their relationships. Human pluripotent stem cell-derived islet models further allow experimental dissection of the conditions that promote endocrine subtype differentiation, including epsilon cells.

Pancreatic endocrine cells, including epsilon cells, are central to metabolic regulation. miR-375 is a microRNA related to diabetes and regulates pancreatic endocrine differentiation, suggesting that post-transcriptional control of endocrine cell development contributes to diabetes pathogenesis. TBK1 regulates regeneration of pancreatic beta-cells, and impaired regeneration is relevant to diabetes. Studying epsilon-cell differentiation may therefore provide insight into endocrine cell plasticity in diabetes.

Insm1 regulates pancreatic endocrine cell differentiation and represses beta- to delta-cell transdifferentiation, indicating that loss of normal transcriptional control can lead to changes in endocrine cell identity. Such plasticity is relevant to understanding how islet cell composition changes in disease. Epsilon cells are part of the normal endocrine repertoire, and their differentiation may be affected by the same regulatory networks that control other endocrine subtypes.

Reconstruction of endocrine subtype-complete human pluripotent stem cell-derived islets with capacity for hypoglycemia protection in vivo demonstrates progress toward functional islet replacement. These models include multiple endocrine subtypes and provide a platform to study epsilon-cell differentiation in vitro. Understanding GO:0090104 may help optimize differentiation protocols for generating specific endocrine cell types for research and therapeutic applications.

Single-cell RNA sequencing enables mapping of human and mouse pancreas cell populations, including rare endocrine subtypes such as epsilon cells. This method reveals inter- and intra-cell population structure and can identify transcriptional signatures associated with epsilon-cell differentiation. Computational tools such as moscot allow mapping of cells through time and space, which can be applied to developmental trajectories.

Human pluripotent stem cell-derived islets can be generated with endocrine subtype completeness, providing a controlled system to study epsilon-cell differentiation. These models allow functional testing, including capacity for hypoglycemia protection in vivo. Differentiation protocols can be combined with genetic perturbation to identify regulators of epsilon-cell fate.

CRISPR-based knockout, point mutation, knock-in, and overexpression approaches can be used to test the function of candidate genes in pancreatic endocrine differentiation. For example, domain-specific mutations in Insm1 have been used to dissect its role in endocrine cell differentiation. Such perturbations can be combined with single-cell readouts to assess effects on rare endocrine populations.

Tagged knock-in reporters can visualize the expression of ghrelin or other markers during epsilon-cell differentiation. Imaging of stem cell-derived islets can confirm the presence of endocrine subtypes. These methods complement transcriptomic and genetic approaches.

Researchers studying pancreatic epsilon cell differentiation-related genes often need to determine whether a candidate gene is causally involved in the differentiation, maintenance, or function of ghrelin-secreting endocrine cells. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations in pancreatic cell lines and stem cell-derived islet models, supporting mechanistic studies of GO:0090104.

GO:0090104, pancreatic epsilon cell differentiation, defines the process by which unspecialized cells become ghrelin-secreting pancreatic epsilon cells. This process is part of the broader program of pancreatic endocrine development, which is controlled by transcription factors such as Insm1, signaling pathways such as TBK1, and post-transcriptional regulators such as miR-375. Single-cell transcriptomic maps and stem cell-derived islet models provide powerful tools to study rare endocrine subtypes, including epsilon cells. Understanding epsilon-cell differentiation may inform diabetes research and regenerative medicine. Researchers can leverage CRISPR-based knockout, point mutation, knock-in, overexpression, and library screening approaches to dissect the genetic control of pancreatic epsilon cell differentiation. EDITGENE offers these services to support mechanistic studies and therapeutic development in this field.